Minerva Neurosciences reported $-4.37M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Adma Biologics USD 53.66M 5.57M Jun/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
AstraZeneca USD 4.66B 1.5B Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Cipla INR 10.43B 1.55B Sep/2026
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 2.64B 116M Dec/2025
Eli Lilly USD 13.09B 635M Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.85B 5.03B Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024